Literature DB >> 33038346

A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans.

Christian Grillon1, Monique Ernst2.   

Abstract

This review introduces a research strategy that may radically transform the pursuit of new anxiolytics, via the use of human models of anxiety in healthy individuals. Despite enormous investments in developing novel pharmacological treatments for anxiety disorders, pharmacotherapy for these conditions remains suboptimal. Most candidate anxiolytics from animal studies fail in clinical trials. We propose an additional screening step to help select candidate anxiolytics before launching clinical trials. This intermediate step moves the evidence for the potential anxiolytic property of candidate drugs from animals to humans, using experimental models of anxiety in healthy individuals. Anxiety-potentiated startle is a robust translational model of anxiety. The review of its face, construct, and predictive validity as well as its psychometric properties in humans establishes it as a promising tool for anxiolytic drug development. In conclusion, human models of anxiety may stir a faster, more efficient path for the development of clinically effective anxiolytics.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; Anxiolytics; Drug development; Human models; Startle

Mesh:

Substances:

Year:  2020        PMID: 33038346      PMCID: PMC7736469          DOI: 10.1016/j.neubiorev.2020.09.024

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  87 in total

Review 1.  Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.

Authors:  Christian Grillon; Oliver J Robinson; Brian Cornwell; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2019-06-21       Impact factor: 7.853

Review 2.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 3.  Failed drug discovery in psychiatry: time for human genome-guided solutions.

Authors:  Andreas Papassotiropoulos; Dominique J F de Quervain
Journal:  Trends Cogn Sci       Date:  2015-02-27       Impact factor: 20.229

Review 4.  Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors.

Authors:  Inga D Neumann; Rainer Landgraf
Journal:  Trends Neurosci       Date:  2012-09-11       Impact factor: 13.837

5.  Startle potentiation to uncertain threat as a psychophysiological indicator of fear-based psychopathology: An examination across multiple internalizing disorders.

Authors:  Stephanie M Gorka; Lynne Lieberman; Stewart A Shankman; K Luan Phan
Journal:  J Abnorm Psychol       Date:  2016-11-17

6.  Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.

Authors:  Boadie W Dunlop; Elisabeth B Binder; Dan Iosifescu; Sanjay J Mathew; Thomas C Neylan; Julius C Pape; Tania Carrillo-Roa; Charles Green; Becky Kinkead; Dimitri Grigoriadis; Barbara O Rothbaum; Charles B Nemeroff; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2017-07-04       Impact factor: 13.382

Review 7.  Oxytocin in General Anxiety and Social Fear: A Translational Approach.

Authors:  Inga D Neumann; David A Slattery
Journal:  Biol Psychiatry       Date:  2015-06-10       Impact factor: 13.382

8.  Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.

Authors:  Eduardo Dunayevich; Janelle Erickson; Louise Levine; Ronald Landbloom; Darryle D Schoepp; Gary D Tollefson
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

Review 9.  LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.

Authors:  Darryle D Schoepp; Rebecca A Wright; Louise R Levine; Brenda Gaydos; William Z Potter
Journal:  Stress       Date:  2003-09       Impact factor: 3.493

10.  Epidemiology of anxiety disorders in the 21st century.

Authors:  Borwin Bandelow; Sophie Michaelis
Journal:  Dialogues Clin Neurosci       Date:  2015-09       Impact factor: 5.986

View more
  7 in total

Review 1.  Corticotropin Releasing Hormone Signaling in the Bed Nuclei of the Stria Terminalis as a Link to Maladaptive Behaviors.

Authors:  Claire Emily Young; Qingchun Tong
Journal:  Front Neurosci       Date:  2021-03-19       Impact factor: 4.677

2.  Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research.

Authors:  Reilly R Kayser; Margaret Haney; Helen Blair Simpson
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

3.  Model of theta frequency perturbations and contextual fear memory.

Authors:  Giuseppe Castegnetti; Daniel Bush; Dominik R Bach
Journal:  Hippocampus       Date:  2021-02-03       Impact factor: 3.899

Review 4.  Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.

Authors:  Mark J Millan
Journal:  Ther Adv Psychopharmacol       Date:  2022-06-30

5.  Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety.

Authors:  Stephanie M Gorka; Kia J Khorrami; Charles A Manzler; K Luan Phan
Journal:  Transl Psychiatry       Date:  2022-08-02       Impact factor: 7.989

6.  Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole.

Authors:  Mikhail V Voronin; Yulia V Vakhitova; Inna P Tsypysheva; Dmitry O Tsypyshev; Inna V Rybina; Rustam D Kurbanov; Elena V Abramova; Sergei B Seredenin
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 7.  Cross-species anxiety tests in psychiatry: pitfalls and promises.

Authors:  Dominik R Bach
Journal:  Mol Psychiatry       Date:  2021-09-24       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.